Results 111 to 120 of about 2,435 (185)

Phosphatase targeting in Luminal B breast cancer: PGP.

Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2).  Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B ...
openaire   +3 more sources

Quercetin's antitumor effect in bladder cancer: Synergistic regulation of gut microbiota and l-serine metabolic pathway. [PDF]

Acta Pharm Sin B
Zhai Z, Yang F, Feng R, Zhang H, Wang J, Zuo H, Yang X, Ye M, Xu H, Hu J, Lu J, Zhao Y, Song J, Zhang Y, Wang Y, Xing N.   +15 more
europepmc   +1 more source

Therapeutic targeting in breast cancer for the treatment of lung metastasis: SHB.

Metastasis is the major cause of death from cancer and metastasis to the lung in breast cancer is difficult to treat and heterogeneous in nature, complicating its management (1-5).  We recently utilized whole transcriptome technologies to define the full complement of differentially expressed kinases and phosphatases in HER2+ breast cancer: in the ...
openaire   +6 more sources

Catalytic site targeting in HER2+ breast cancer for the treatment of CNS metastasis: PSPH.

Up to 50% of patients with HER2+ subtype breast cancer develop metastasis to the central nervous system, most commonly the brain, demanding rapid therapeutic approaches to limit spread of the HER2+ primary tumor to distant sites (1-3).  We recently described the existence of a group of genes that reside proximal to ERBB2 (the gene that encodes the ...
openaire   +5 more sources

Therapeutic targeting in breast cancer for the treatment of metastasis to the skeletal system: PTPRA.

We study breast cancer in humans as a model for understanding cancer as a system in its entirety and as a life cycle, including cell of origin, transformation, subtype selection, biology and ecology of the primary tumor, the tumor microenvironment, tumor immunology and surveillance, dissemination via the circulating tumor cell, metastasis to the lymph ...
openaire   +9 more sources

LIS1 mediated Schwann cell reprogramming enhances perineural invasion by activating the serine/NMDAR/AKT signaling pathway in head and neck squamous carcinoma. [PDF]

Cancer Cell Int
Liu J, Dai A, Liu Y, Zhang Y, Yan B, Jin D, Wang F, Gao L.   +7 more
europepmc   +1 more source

Development of the membranous labyrinth in E9.5 to E14.5 C57BL/6N mouse embryos. Stage specific metric and descriptive reference data and their use for identifying malformations. [PDF]

Front Cell Dev Biol
Maurer-Gesek B, Geyer SH, Weninger WJ.
europepmc   +1 more source

Recent progress in serine metabolism reprogramming in tumors and strategies for serine deprivation. [PDF]

Front Oncol
Liu H, Liu Y.
europepmc   +1 more source

Metabolic remodeling and immune evasion in glioblastoma: a focus on serine and lipid networks. [PDF]

Front Oncol
Jiang D, Wang C, Zhao Y, Li Y.
europepmc   +1 more source

Validity of a CB-NAAT assay in diagnosing tuberculosis in comparison to culture: A study from an urban area of South India

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2020
Aishwarya Raj, Shrikala Baliga, M. Suchitra Shenoy, B. Dhanashree, P. Prasanna Mithra, Smitha K. Nambiar, Leesha Sharon   +6 more
doaj   +1 more source